Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA; Division of Urology, Washington University School of Medicine, St Louis, MO 63110, USA.
Hum Pathol. 2019 Jul;89:99-108. doi: 10.1016/j.humpath.2019.04.009. Epub 2019 May 3.
Androgens and estrogens, working together, promote prostate cancer (PRCA) initiation and progression, with androgens acting via androgen receptor (AR) and estrogens acting primarily through estrogen receptor α (ERα). While the interplay between these steroid hormones has been established, the interaction between steroid hormone receptors in prostatic disease remains unstudied. The goal of this study was to objectively determine the incidence, stage specificity, and tissue/cell type specificity of AR and ERα expression, both independently and simultaneously, during the progression of PRCA. Using multiplexed immunohistochemistry and multispectral imaging analysis, AR, ERα, and smooth muscle α-actin expression was detected and quantitated in benign prostate tissue (BPT), high-grade prostatic intraepithelial neoplasia (HGPIN), PRCA, and metastasis (MET) from patient specimens (n=340). Epithelial AR expression was significantly increased in HGPIN, PRCA, and MET compared with BPT, whereas ERα expression in epithelial and stromal cells was highest in HGPIN. With analysis of AR and ERα coexpression, we identified a unique population of double-positive (AR/ERα) cells that increased in HGPIN specimens in both the stroma and the epithelium. Double-negative (AR/ERα) cells significantly decreased across PRCA progression, from 65% in BPT to 30% in MET. Preliminary analysis of this AR/ERα population indicates potential cell type specificity in smooth muscle α-actin-negative stromal cells. This study demonstrates stage-, tissue-, and cell type-specific AR and ERα expression changes during PRCA progression, both independently and coexpressed. A more complete understanding of steroid hormones and their receptors in the initiation and progression of prostatic disease may elucidate improved strategies for PRCA prevention or therapy.
雄激素和雌激素共同作用促进前列腺癌(PRCA)的发生和发展,雄激素通过雄激素受体(AR)起作用,雌激素主要通过雌激素受体α(ERα)起作用。虽然这些甾体激素之间的相互作用已经确立,但甾体激素受体在前列腺疾病中的相互作用仍未得到研究。本研究的目的是客观地确定 AR 和 ERα 的表达在 PRCA 进展过程中的发生率、阶段特异性和组织/细胞类型特异性,无论是独立表达还是同时表达。本研究使用多重免疫组化和多光谱成像分析,检测和定量分析了来自患者标本的良性前列腺组织(BPT)、高级别前列腺上皮内瘤变(HGPIN)、PRCA 和转移(MET)中 AR、ERα 和平滑肌α-肌动蛋白的表达(n=340)。与 BPT 相比,HGPIN、PRCA 和 MET 中的上皮 AR 表达明显增加,而上皮和基质细胞中的 ERα 表达在 HGPIN 中最高。通过分析 AR 和 ERα 的共表达,我们在 HGPIN 标本的基质和上皮中鉴定出一种独特的双阳性(AR/ERα)细胞群。双阴性(AR/ERα)细胞在 PRCA 进展过程中显著减少,从 BPT 的 65%减少到 MET 的 30%。对这种 AR/ERα 群体的初步分析表明,平滑肌α-肌动蛋白阴性基质细胞可能具有潜在的细胞类型特异性。本研究表明,在 PRCA 进展过程中,AR 和 ERα 的表达存在独立和共表达的阶段、组织和细胞类型特异性变化。更全面地了解甾体激素及其受体在前列腺疾病的发生和发展中的作用,可能阐明改善 PRCA 预防或治疗的策略。